טוען...
Acquired Hemophilia A Successfully Treated with Rituximab
Acquired hemophilia A (AHA) is a rare bleeding disorder due to the development of specific autoantibodies against factor VIII. The anti-CD20 monoclonal antibody Rituximab has been proven to be effective in obtaining a long-term suppression of inhibitors of AHA, besides other immunosuppressive standa...
שמור ב:
| הוצא לאור ב: | Mediterr J Hematol Infect Dis |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Università Cattolica del Sacro Cuore
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4344169/ https://ncbi.nlm.nih.gov/pubmed/25745551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2015.024 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|